Acute hepatitis due to olmesartan: an uncommon entity

Area of Science:

• Hepatology
• Pharmacology
• Internal Medicine

Background:

• Hypertension is a prevalent cardiovascular condition requiring pharmacologic management.
• Olmesartan is an angiotensin II receptor blocker commonly prescribed for hypertension.
• Drug-induced liver injury is a potential, though uncommon, adverse effect of various medications.

Observation:

• A 54-year-old female with hypertension presented with elevated liver enzymes (hypertransaminasemia).
• The patient had been taking olmesartan (40 mg daily) for one month prior to presentation.
• She also reported significant asthenia and a 7 kg weight loss.

Findings:

• The clinical presentation suggests a possible link between olmesartan therapy and liver enzyme elevation.
• The concurrent symptoms of asthenia and weight loss warrant further investigation into the systemic effects of the medication.
• Further diagnostic workup is necessary to confirm olmesartan-induced hepatotoxicity and rule out other causes.

Implications:

• This case underscores the importance of monitoring liver function in patients treated with olmesartan.
• Clinicians should consider olmesartan as a potential cause of hypertransaminasemia and associated symptoms.
• Early recognition and management of drug-induced liver injury are crucial for patient outcomes.